Arcellx is a clinical-stage biopharmaceutical company developing adaptive and controllable cell therapies for the treatment of patients with cancer and autoimmune diseases. The Arcellx vision is to utilize our novel proprietary platform to bring superior cell therapies to more patients through the care of academic and community practices worldwide. More information can be found at www.arcellx.com.
A2 is dedicated to pushing the boundaries of science to transform medicine and turn the tide on cancer. We are focused on the next frontier in cell therapy: solid tumors.Our approach addresses the central problem of cancer research: tumor-targeted killing. We focus on targets lost in cancer cells, potentially creating breakthrough therapies to treat most cancers.
Immatics combines the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors with the goal of enabling a robust and specific T cell response against these targets. This deep know-how is the foundation for our pipeline of Adoptive Cell Therapies and TCR Bispecifics as well as our partnerships with global leaders in the pharmaceutical industry. We are committed to delivering the power of T cells and to unlocking new avenues for patients in their fight against cancer.
- Locations: Tuebingen and Munich, Germany and Houston, Texas, USA
- Employees: 250 +
- Proprietary pipeline: 7 product candidates, thereof 3 in clinical trials
- Partnered pipeline: 10 programs partnered with Amgen, Genmab, BMS, GSK
- Cancer targets: More than 200 prioritized cancer targets across multiple cancer indications
- IP position: Over 1,550 secured patents worldwide and over 400 granted patents in the US
Kite, a Gilead Company
We are an international and independent pharmaceutical company governed by a non-profit foundation, with headquarters in Suresnes, France. Since opening our first laboratory in 1954, we have been committed to therapeutic progress to serve patient needs with the help of healthcare professionals.
SOTIO is shaping the future of cancer immunotherapies by translating compelling science into patient benefit. Our growing oncology pipeline includes SOT101, a differentiated IL-15 superagonist, BOXR1030, our lead GPC3 CAR-T cell therapy that enters the clinic end of 2021, and SOT102, a Claudin18.2 targeting ADC with best in class properties (IND Q4/2021).
Our T cell therapy R&D Center of Excellence based in Cambridge, Massachusetts is developing novel CAR-T cell therapies for solid tumors utilizing SOTIO’s proprietary technology platform and our GMP cell therapy manufacturing site in Prague, Czech Republic.